BBI Life Sciences Corporation announced unaudited consolidated earnings results for the six months ended June 30, 2017. For the period, the company reported revenue of RMB 220,216,000 against RMB 164,207,000 a year ago. Operating profit was RMB 33,133,000 against RMB 34,297,000 a year ago. Profit before income tax was RMB 33,285,000 against RMB 37,021,000 a year ago. Total profit attributable to equity holders of the company was RMB 29,828,000 or RMB 0.055 per basic and diluted share against RMB 28,733,000 or RMB 0.053 per basic and diluted share a year ago. Net cash used in operating activities was RMB 6,076,000 against net cash from operating activities of RMB 7,846,000 a year ago. Purchase of property, plant and equipment was RMB 76,355,000 against RMB 33,751,000 a year ago. Purchase of intangible assets was RMB 199,000 against RMB 18,000 a year ago. Net profit decreased mainly due to was mainly because Bionics was at its early stage of establishment of market network, and the significant investment in sales, research and development and management expenses led to the loss recorded in the Group's net profit during the Reporting Period.